COPD Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Obstructive Pulmonary Disease pipeline constitutes 65+ key companies continuously working towards developing 75+ Chronic Obstructive Pulmonary Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Chronic Obstructive Pulmonary Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Chronic Obstructive Pulmonary Disease Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Obstructive Pulmonary Disease Market.

Some of the key takeaways from the Chronic Obstructive Pulmonary Disease Pipeline Report: https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav
• Companies across the globe are diligently working toward developing novel Chronic Obstructive Pulmonary Disease treatment therapies with a considerable amount of success over the years.
• Chronic Obstructive Pulmonary Disease companies working in the treatment market are AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others, are developing therapies for the Chronic Obstructive Pulmonary Disease treatment
• Emerging Chronic Obstructive Pulmonary Disease therapies in the different phases of clinical trials are- Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others are expected to have a significant impact on the Chronic Obstructive Pulmonary Disease market in the coming years.
• In August 2026, Expedition Therapeutics secures $115M in Series B funding to support Phase 2 development of its lead DPP1 inhibitor, EXPD-101, for chronic obstructive pulmonary disease (COPD).
• In August 2026, Cipla Limited and its U.S. subsidiary, Cipla USA Inc., have received U.S. FDA approval for their generic version of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) across all three strengths 100/50 mcg, 250/50 mcg, and 500/50 mcg. The product is therapeutically equivalent to Advair Diskus and is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The approval marks Cipla's first dry powder inhaler (DPI) approval from its U.S.-based manufacturing network, strengthening its capabilities in complex respiratory therapies. According to IQVIA, the U.S. market for fluticasone propionate and salmeterol inhalation powder is approximately USD 908 million.
• In May 2026, Results from a randomized clinical study of EP395, an investigational anti-inflammatory macrolide, demonstrated promising anti-inflammatory effects along with a favorable safety profile in patients with stable COPD. The findings underscore ongoing efforts to develop innovative non-biologic treatment strategies for the management of chronic obstructive pulmonary disease.
• In April 2026, AstraZeneca announced further positive results from the Phase III MIRANDA trial, showing that tozorakimab achieved statistically significant reductions in COPD exacerbations among patients treated with standard inhaled therapies. These findings further reinforce the therapy's promising late-stage clinical potential.
• In March 2026, AstraZeneca's tozorakimab successfully met the primary endpoint in both the Phase III OBERON and TITANIA studies, demonstrating a significant reduction in moderate-to-severe COPD exacerbations. The IL-33-targeted monoclonal antibody showed efficacy across a diverse patient population, including both current and former smokers.
• In January 2026, Findings from the Phase III PACE trial assessing bisoprolol for the prevention of adverse cardiovascular events in patients with COPD were published, providing important insights into the management of cardiovascular comorbidities within the COPD population.
• In April 2025, Connect Biopharma Holdings Limited (Nasdaq: CNTB), a clinical-stage biopharmaceutical company dedicated to advancing treatments for asthma and chronic obstructive pulmonary disease (COPD), has received encouraging feedback from its Type C meeting with the U.S. Food and Drug Administration (FDA), specifically the Division of Pulmonology, Allergy, and Critical Care within the Office of Immunology and Inflammation.
• In March 2025, SMSbiotech achieved a major milestone in advancing its regenerative medicine platform, receiving approval to initiate a Phase I clinical trial in Australia (registration number: ANZCTR12624001140549p). The trial aims to assess the safety and tolerability of the company's novel Small Mobile stem (SMS) cell therapy for treating Chronic Obstructive Pulmonary Disease (COPD).
• In January 2025, Aer Therapeutics ("Aer"), a biopharmaceutical company focused on developing innovative inhaled therapies for mucus-related lung diseases, announced that the first patient has been dosed in its Phase 2a proof-of-concept (POC) clinical trial of fexlamose (previously known as AER-01) for Chronic Obstructive Pulmonary Disease (COPD).
• In September 2024, GSK's asthma drug Nucala (mepolizumab) achieved its primary endpoint in a Phase III trial for treating patients with chronic obstructive pulmonary disease (COPD). Results from the MATINEE study revealed that adding Nucala to inhaled maintenance therapy significantly lowered the annualized rate of moderate or severe exacerbations compared to placebo.
• In January 2024, Theravance Biopharma, Inc. (NASDAQ: TBPH) has released findings from the Phase 4 PIFR-2 trial of YUPELRI® (revefenacin) inhalation solution, the sole once-daily, nebulized long-acting muscarinic antagonist (LAMA) authorized in the U.S. for COPD maintenance therapy. The PIFR-2 study aimed to illustrate superior lung function enhancement with YUPELRI administered via standard jet nebulizer versus Spiriva® (tiotropium) delivered through a dry powder inhaler (Spiriva® HandiHaler®) in severe to very severe COPD patients with suboptimal peak inspiratory flow rate (PIFR).
• In April 2024, Amgen (NASDAQ: AMGN) shared an update on the Phase 2a COURSE trial results for TEZSPIRE® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which will be presented at the American Thoracic Society (ATS) 2024 International Conference. The trial, which investigated tezepelumab in patients with moderate to very severe COPD across various eosinophil levels and inflammatory drivers, showed promising results. The study did not exclude patients based on baseline eosinophil count (BEC) and enrolled a diverse group. Tezepelumab reduced the annualized rate of moderate or severe COPD exacerbations by 17% compared to placebo, though the result did not reach statistical significance.

Chronic Obstructive Pulmonary Disease Overview
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that causes breathing difficulties due to airflow obstruction. It encompasses conditions such as chronic bronchitis and emphysema, primarily resulting from long-term exposure to irritants like cigarette smoke, air pollution, and occupational dust. Symptoms include persistent cough, mucus production, wheezing, and shortness of breath, especially during physical activity. COPD is characterized by its chronic nature, often leading to worsening lung function over time. While there is no cure, management options include medications, pulmonary rehabilitation, and lifestyle changes, such as smoking cessation, to improve quality of life and reduce symptoms.

Get a Free Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Emerging Chronic Obstructive Pulmonary Disease Drugs Under Different Phases of Clinical Development Include:
• Benralizumab: AstraZeneca
• Dupilumab: Sanofi
• Tezepelumab: Amgen
• SNG001: Synairgen
• GSK3923868: GlaxoSmithKline
• Ensifentrine: Verona Pharma
• SAR440340: Regeneron Pharma
• CHF 6001: Chiesi Farmaceutici S.p.A
• QBW-251: Novartis
• Tezepelumab: AstraZeneca
• Anti-ST2: Genentech
• PBF-680: Palobiofarma
• PUR1800: Pulamtrix

Chronic Obstructive Pulmonary Disease Route of Administration
Chronic Obstructive Pulmonary Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular

Chronic Obstructive Pulmonary Disease Molecule Type
Chronic Obstructive Pulmonary Disease Products have been categorized under various Molecule types, such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide

Chronic Obstructive Pulmonary Disease Pipeline Therapeutics Assessment
• Chronic Obstructive Pulmonary Disease Assessment by Product Type
• Chronic Obstructive Pulmonary Disease By Stage and Product Type
• Chronic Obstructive Pulmonary Disease Assessment by Route of Administration
• Chronic Obstructive Pulmonary Disease By Stage and Route of Administration
• Chronic Obstructive Pulmonary Disease Assessment by Molecule Type
• Chronic Obstructive Pulmonary Disease by Stage and Molecule Type

DelveInsight's Chronic Obstructive Pulmonary Disease Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Chronic Obstructive Pulmonary Disease product details are provided in the report. Download the Chronic Obstructive Pulmonary Disease pipeline report to learn more about the emerging Chronic Obstructive Pulmonary Disease therapies
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key companies in the Chronic Obstructive Pulmonary Disease Therapeutics Market include:
Key companies developing therapies for Chronic Obstructive Pulmonary Disease are - Afimmune, Allakos, Amgen/AstraZeneca, Arrowhead Pharmaceuticals, Astellas Pharma, AstraZeneca, Boehringer-Ingelheim, Brickell Biotech, Chiesi Farmaceutici S.p.A., Chiesi USA, Inc., Dimerix, EpiEndo Pharmaceuticals, Genentech, GlaxoSmithkline, GSNOR Therapeutics, InMed Pharmaceuticals, Ionis Pharmaceuticals, KeyMed Biosciences, Laboratoires SMB, Mereo BioPharma, Meridigen Biotech, Nephron Pharmaceuticals, Novartis, Pulmatrix Inc., Pulmotect, Quercegen Pharmaceuticals, Regend Therapeutics, Regeneron Pharmaceuticals/Sanofi, Sulfateq BV, Synairgen, Verona Pharma, Vertex Pharmaceuticals, and several others.

Chronic Obstructive Pulmonary Disease Pipeline Analysis:
The Chronic Obstructive Pulmonary Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Obstructive Pulmonary Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Obstructive Pulmonary Disease Treatment.
• Chronic Obstructive Pulmonary Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Obstructive Pulmonary Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Obstructive Pulmonary Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Obstructive Pulmonary Disease drugs and therapies
https://www.delveinsight.com/sample-request/chronic-obstructive-pulmonary-disease-copd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Chronic Obstructive Pulmonary Disease Pipeline Market Drivers
• Rising global prevalence of COPD, driven by smoking, air pollution, occupational exposures, and aging populations, is increasing demand for innovative therapies.
• Significant unmet medical need for disease-modifying treatments beyond symptomatic management is fueling pipeline development.
• Growing awareness and improved diagnosis rates are expanding the identified patient population eligible for treatment.
• Advances in biologics and targeted therapies, particularly for eosinophilic and inflammatory COPD phenotypes, are driving innovation.
• Increasing research into regenerative medicine and novel anti-inflammatory mechanisms is broadening therapeutic opportunities.

Chronic Obstructive Pulmonary Disease Pipeline Market Barriers
• Complex and heterogeneous disease biology makes it challenging to develop universally effective therapies.
• High clinical trial costs and lengthy study durations are required to demonstrate meaningful improvements in lung function and exacerbation rates.
• Difficulty in identifying reliable biomarkers and clinical endpoints can complicate drug development and regulatory approval.
• Stringent regulatory requirements for demonstrating long-term efficacy and safety may delay product approvals.
• High failure rates in late-stage clinical trials due to limited efficacy in diverse patient populations remain a key concern.

Scope of Chronic Obstructive Pulmonary Disease Pipeline Drug Insight
• Coverage: Global
• Key Chronic Obstructive Pulmonary Disease Companies: AstraZeneca, Sanofi, Amgen, Synairgen, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Chiesi Farmaceutici S.p.A, Novartis, Genentech, Palobiofarma, Pulamtrix, and others
• Key Chronic Obstructive Pulmonary Disease Therapies: Benralizumab, Dupilumab, Tezepelumab, SNG001, GSK3923868, Ensifentrine, SAR440340, CHF 6001, QBW-251, Tezepelumab, Anti-ST2, PBF-680, PUR1800, and others
• Chronic Obstructive Pulmonary Disease Therapeutic Assessment: Chronic Obstructive Pulmonary Disease current marketed and Chronic Obstructive Pulmonary Disease emerging therapies
• Chronic Obstructive Pulmonary Disease Market Dynamics: Chronic Obstructive Pulmonary Disease market drivers and Chronic Obstructive Pulmonary Disease market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.